Literature DB >> 15072868

Safety and efficacy of percutaneous nephrolithotomy in patients with neurogenic bladder dysfunction.

Jonathan N Rubenstein1, Chris M Gonzalez, Lynn W Blunt, J Quentin Clemens, Robert B Nadler.   

Abstract

OBJECTIVES: To review our experience performing percutaneous nephrolithotomy (PNL) on patients with neurogenic bladder dysfunction with special attention paid to the risks of surgical complications and stone recurrence. Patients with neurogenic bladder dysfunction with or without urinary diversion are at increased risk of urolithiasis, surgical complications, and recurrent stone disease.
METHODS: We retrospectively reviewed the 23 patients with neurogenic bladder dysfunction who underwent PNL at our institution. Neurologic lesions included spina bifida, traumatic spinal cord injury, exstrophy/epispadias, neonatal meningitis, stroke, and spine chondrosarcoma. Bladder management included ileal conduit (n = 8), intermittent catheterization (n = 7), indwelling catheter (n = 7), and ureterosigmoidostomy (n = 1).
RESULTS: We performed 100 procedures on 47 renal units (17 bilateral, 7 with recurrent stones). Urinary tract infection/colonization was seen in 21 of 23 patients, most of whom had more than one organism. The stone-free rate was 96%. Six patients required three or more procedures, each had a complete staghorn calculus. In an average of 36 months of follow-up, 10 patients (46%) had recurrent stone disease requiring intervention, and 5 patients (23%) underwent repeat PNL. The stone composition analysis revealed mainly infection-related stones.
CONCLUSIONS: PNL in patients with neurogenic voiding dysfunction is safe and effective, with outcomes comparable to that of patients without such lesions. The complication rate is small but statistically significant. It is important to obtain adequate urine cultures, because renal pelvis and bladder culture data may differ and affect the outcome. Risk factors for recurrent stone disease include a high spinal cord lesion, indwelling urinary catheter, and ureterosigmoidostomy.

Entities:  

Mesh:

Year:  2004        PMID: 15072868     DOI: 10.1016/j.urology.2003.11.027

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Complications of surgical management of upper tract calculi in spina bifida patients: analysis of nationwide data.

Authors:  Hsin-Hsiao S Wang; John S Wiener; Michael N Ferrandino; Michael E Lipkin; Jonathan C Routh
Journal:  J Urol       Date:  2014-09-28       Impact factor: 7.450

Review 2.  Stones in special situations.

Authors:  Mordechai Duvdevani; Stavros Sfoungaristos; Karim Bensalah; Benoit Peyronnet; Amy Krambeck; Sanjay Khadji; Ahmet Muslumanuglu; David Leavitt; Jude Divers; Zeph Okeke; Arthur Smith; Janelle Fox; Michael Ost; Andreas J Gross; Hassan Razvi
Journal:  World J Urol       Date:  2017-03-07       Impact factor: 4.226

3.  Outcomes of percutaneous nephrolithotomy in spinal cord injury patients as compared to a matched cohort.

Authors:  Kristin G Baldea; Robert H Blackwell; Srikanth Vedachalam; Anai N Kothari; Paul C Kuo; Gopal N Gupta; Thomas M T Turk
Journal:  Urolithiasis       Date:  2016-12-20       Impact factor: 3.436

4.  Flexible ureteroscopic laser lithotripsy for upper urinary tract stone disease in patients with spinal cord injury.

Authors:  Abdulkadir Tepeler; Brian C Sninsky; Stephen Y Nakada
Journal:  Urolithiasis       Date:  2015-05-19       Impact factor: 3.436

5.  Managing the urinary tract in spinal cord injury.

Authors:  Simon C W Harrison
Journal:  Indian J Urol       Date:  2010-04

Review 6.  Surgical management of urolithiasis in spinal cord injury patients.

Authors:  Philippe Nabbout; Gennady Slobodov; Daniel J Culkin
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

7.  Ureteroscopy in patients with spinal cord injury: outcomes from a spinal injury unit and a review of literature.

Authors:  Sarah Prattley; Rachel Oliver; Francesca New; Melissa Davies; James Brewin
Journal:  Transl Androl Urol       Date:  2019-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.